Evidence map›Paper›PMID 41063543›Full record

ReviewPharmacoepidemiology and drug safety2025

Recommendations to Enable Broader Use of Real-World Evidence to Inform Decision-Making Throughout Pharmacovigilance Signal Management.

G Niklas Norén, Katherine Donegan, Monica A Muñoz, Thamir M Alshammari, Nicole Pratt, Gianmario Candore, Daniel Morales, Peter Rijnbeek, Andrew Bate, Rodrigo Postigo and 5 more

Abstract readReview
In one paragraph

Review in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

G Niklas NorénUppsala Monitoring Centre, Uppsala, Sweden.ORCID https://orcid.org/0000-0002-4595-230X
Katherine DoneganMedicines and Healthcare Products Regulatory Agency, London, UK.ORCID https://orcid.org/0000-0002-3488-9130
Monica A MuñozUS Food and Drug Administration, Silver Spring, Maryland, USA.ORCID https://orcid.org/0000-0001-9754-1986
Thamir M AlshammariJazan University, Jazan, Saudi Arabia.ORCID https://orcid.org/0000-0002-5630-2468
Nicole PrattUniversity of South Australia, Adelaide, Australia.ORCID https://orcid.org/0000-0001-8730-8910
Gianmario CandoreBayer AG, Berlin, Germany.ORCID https://orcid.org/0000-0002-7299-7300
Daniel MoralesEuropean Medicines Agency, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-0063-8069
Peter RijnbeekErasmus University Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0003-0621-1979
Rodrigo PostigoEuropean Medicines Agency, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-7441-9424
Sengwee TohHarvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-5160-0810
Gianluca TrifiròUniversity of Verona, Italy.ORCID https://orcid.org/0000-0003-1147-7296
Montse Soriano GabarroBayer AG, Berlin, Germany.ORCID https://orcid.org/0000-0002-3825-0182
Alison CaveMedicines and Healthcare Products Regulatory Agency, London, UK.
Patrick B RyanJanssen Research and Development, Titusville, New Jersey, USA.

Funding

International Society for Pharmacoepidemiology
6 · The paper itself

Abstract

introductionDespite substantial investments in analytical infrastructure and scientific research related to the development and analysis of real-world evidence in support of signal management, the impact on routine pharmacovigilance activities has been limited. Most organizations still rely largely on analyses of individual case reports and pre-existing evidence - especially during signal detection and validation.

objectiveThis paper presents a set of recommendations for efforts to enable broader use of real-world evidence throughout pharmacovigilance signal management, in the future. OUTCOME: The recommendations regard streamlined data access, data harmonization and use of reproducible analytical workflows to enable rapid and robust evidence generation. They emphasize the need for cross-disciplinary collaboration and for organizational adaptations to ensure adequate competence and supporting processes, including principles for how to integrate new types of evidence in decision-making. The execution of pilot studies under realistic conditions and the dissemination of their findings are highlighted as important steps toward defining the proposed change and driving progress in this area. This manuscript is endorsed by the International Society for Pharmacoepidemiology (ISPE).

Indexed as

Adverse Drug Reaction Reporting SystemsDecision MakingPharmacoepidemiologyPharmacovigilanceHumansdecision‐makingpharmacovigilancereal‐world datareal‐world evidenceregulatory sciencesignal management

Identifiers

PMID41063543
PMCPMC12508715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.